NOVO-NORDISK AS BDK 0.1 news, videos and press releases
For more news please use our advanced search feature.
NOVO-NORDISK AS BDK 0.1 - More news...
NOVO-NORDISK AS BDK 0.1 - More news...
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
- Novo Nordisk A/S - Articles of Association, April 2024
- Novo Nordisk A/S – Reduction of the share capital
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - Articles of Association 2024
- Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
- Resolutions from the Annual General Meeting of Novo Nordisk A/S
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
- Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
- Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial